MYGN vs. CLDX, NTLA, NEOG, QDEL, LNTH, HRMY, AMRX, NAMS, NMRA, and TWST
Should you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Neogen (NEOG), QuidelOrtho (QDEL), Lantheus (LNTH), Harmony Biosciences (HRMY), Amneal Pharmaceuticals (AMRX), NewAmsterdam Pharma (NAMS), Neumora Therapeutics (NMRA), and Twist Bioscience (TWST). These companies are all part of the "medical" sector.
Myriad Genetics (NASDAQ:MYGN) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.
Myriad Genetics has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.
Celldex Therapeutics has lower revenue, but higher earnings than Myriad Genetics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.
Myriad Genetics has a net margin of -34.96% compared to Celldex Therapeutics' net margin of -2,054.46%. Myriad Genetics' return on equity of -8.03% beat Celldex Therapeutics' return on equity.
99.0% of Myriad Genetics shares are held by institutional investors. 2.0% of Myriad Genetics shares are held by insiders. Comparatively, 3.7% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Celldex Therapeutics received 135 more outperform votes than Myriad Genetics when rated by MarketBeat users. Likewise, 74.84% of users gave Celldex Therapeutics an outperform vote while only 53.46% of users gave Myriad Genetics an outperform vote.
Myriad Genetics currently has a consensus price target of $23.17, indicating a potential upside of 23.03%. Celldex Therapeutics has a consensus price target of $66.00, indicating a potential upside of 69.32%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than Myriad Genetics.
In the previous week, Celldex Therapeutics had 4 more articles in the media than Myriad Genetics. MarketBeat recorded 9 mentions for Celldex Therapeutics and 5 mentions for Myriad Genetics. Celldex Therapeutics' average media sentiment score of 0.29 beat Myriad Genetics' score of -0.21 indicating that Celldex Therapeutics is being referred to more favorably in the news media.
Summary
Celldex Therapeutics beats Myriad Genetics on 11 of the 18 factors compared between the two stocks.
Get Myriad Genetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Myriad Genetics Competitors List
Related Companies and Tools
